EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Concordance‐discordance between apolipoprotein B and lipid biomarkers in predicting 20‐year atherosclerotic cardiovascular disease risk: The ATTICA study (2002–2022)

Sofia-Panagiota Giannakopoulou, Smaragdi Antonopoulou, Fotios Barkas, Evangelos Liberopoulos, Christina Chrysohoou, Petros P Sfikakis, Christos Pitsavos, Costas Tsioufis, Demosthenes Panagiotakos iD

European Journal of Clinical Investigation · 2025

DOI: 10.1111/eci.70077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Sofia-Panagiota Giannakopoulou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University, Athens, Greece. Hauptthemen laut MEDLINE: Lipoprotein(a), Cholesterol, LDL, Atherosclerosis, Apolipoprotein B-100. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Autism Speaks, Hellenic Cardiological Society, Hellenic Atherosclerosis Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A strong correlation exists between low‐density lipoprotein cholesterol (LDL‐C), non‐high‐density lipoprotein cholesterol (non‐HDL‐C), and apolipoprotein B100 (apoB). However, evidence suggests that LDL‐C and non‐HDL‐C may underestimate apoB, potentially obscuring residual cardiovascular risk. Furthermore, interactions between apoB and lipoprotein(a) are implicated in atherogenesis. This study sought to determine whether discordance between apoB, LDL‐C, non‐HDL‐C, or lipoprotein(a) is associated with 20‐year atherosclerotic cardiovascular disease (ASCVD) risk within a cohort of apparently healthy adults.

Methods

A cohort of 3042 CVD‐free adults residing in greater Athens, Greece, was recruited in 2002. A 20‐year follow‐up was conducted in 2022, comprising n = 2169 participants, of which n = 1988 had complete data for cardiovascular disease incidence. Discordance between biomarkers was defined based on recommended lipid thresholds. Cox proportional hazards models were used to assess the association between discordant/concordant biomarker pairs and 20‐year ASCVD risk.

Results

ApoB strongly correlated with LDL‐C and non‐HDL‐C, though concordance was limited. Increased 20‐year ASCVD cumulative incidence with elevated apoB levels, beyond LDL‐C, non‐HDL‐C, and lipoprotein(a). Discordance analysis revealed that elevated apoB independently predicted increased 20‐year ASCVD risk, regardless of non‐HDL‐C and lipoprotein(a). However, this effect was observed only on concomitantly elevated LDL‐C levels. Incorporating apoB into the assessment of traditional modifiable risk factors elucidated part of the previously residual 20‐year ASCVD risk, especially in individuals with elevated LDL‐C, non‐HDL‐C, or lipoprotein(a) levels.

Conclusions

ApoB may be a superior biomarker for assessing long‐term ASCVD risk, indicating that apoB‐containing lipoprotein particle number, rather than cholesterol content, is a more robust predictor of ASCVD risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lipoprotein(a)Cholesterol, LDLAtherosclerosisApolipoprotein B-100Apolipoproteins BCardiovascular DiseasesHumansMaleFemaleMiddle AgedBiomarkersGreeceAdultAgedProportional Hazards ModelsCholesterol, HDLRisk FactorsIncidence

Stichwörter der Autor:innen

LDL‐Capolipoprotein Batherosclerotic cardiovascular disease riskdiscordancelipoprotein(a)non‐HDL‐C

Substanzen

BiomarkersLipoprotein(a)Cholesterol, LDLApolipoprotein B-100Apolipoproteins BAPOB protein, humanCholesterol, HDL

Autor:innen und Institutionen

  • Department of Nutrition and Dietetics, School of Health Sciences and Education, Harokopio University, Athens, Greece.
  • Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
  • First Department of Propaedeutic and Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
  • First Cardiology Clinic, Medical School, National and Kapodistrian University of Athens, Hippokration Hospital, Athens, Greece.

ORCID-Profile: Demosthenes Panagiotakos

Förderung

  • Autism Speaks
  • Hellenic Cardiological Society
  • Hellenic Atherosclerosis Society

Zitieren

APA

Giannakopoulou, S. P., Antonopoulou, S., Barkas, F., Liberopoulos, E., Chrysohoou, C., Sfikakis, P. P., Pitsavos, C., Tsioufis, C., & Panagiotakos, D. (2025). Concordance‐discordance between apolipoprotein B and lipid biomarkers in predicting 20‐year atherosclerotic cardiovascular disease risk: The ATTICA study (2002–2022). European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70077

Vancouver

Giannakopoulou SP, Antonopoulou S, Barkas F, Liberopoulos E, Chrysohoou C, Sfikakis PP, et al. Concordance‐discordance between apolipoprotein B and lipid biomarkers in predicting 20‐year atherosclerotic cardiovascular disease risk: The ATTICA study (2002–2022). European Journal of Clinical Investigation. 2025. doi:10.1111/eci.70077

BibTeX
@article{Giannakopoulou2025,
  author = {Giannakopoulou, Sofia-Panagiota and Antonopoulou, Smaragdi and Barkas, Fotios and Liberopoulos, Evangelos and Chrysohoou, Christina and Sfikakis, Petros P and Pitsavos, Christos and Tsioufis, Costas and Panagiotakos, Demosthenes},
  title = {Concordance‐discordance between apolipoprotein B and lipid biomarkers in predicting 20‐year atherosclerotic cardiovascular disease risk: The ATTICA study (2002–2022)},
  journal = {European Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1111/eci.70077}
}
Kostenlos starten →